Submitted: 07 Mar 2022
Revision: 17 Apr 2022
Accepted: 17 Apr 2022
ePublished: 23 Jul 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Dis Diagn. 2022;11(3): 100-104.
doi: 10.34172/ddj.2022.19
  Abstract View: 25
  PDF Download: 15

Original Article

Heparanase Gene Hypomethylation as a Potential Biomarker for Precision Screening of Bladder Cancer

Bai-sheng Xu 1 ORCID logo, Yan-ying Jiang 1 ORCID logo, Caizhi Liao 2* ORCID logo, Min-bo Yan 3* ORCID logo

1 The First People’s Hospital Of Xiushui, Jiujiang, Jiangxi Province, 332400, P.R. China.
2 Creative Biosciences (Guangzhou) Co., Ltd. Guangzhou, 510535, P.R. China.
3 The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong Province, 519000, P.R. China.
*Corresponding Authors: Correspondence to Caizhi Liao, Email: , Email: liaocaizhi@creativebio.cn; Correspondence to Min-bo Yan, Email: , Email: 13870834578@163.com


Background: Epigenetics has been playing an increasingly important role in the study of the origin and development of bladder cancer (BC). This study aimed to investigate the correlation between promoter hypomethylation of the heparanase (HPSE) gene and clinicopathologic characteristics of bladder cancer (BC).

Materials and Methods: The promoter hypomethylation profile was evaluated by methylation-specific polymerase chain reaction (PCR) using 27 BC tissue specimens and 15 normal control specimens. The aim was to help decipher the underlying relationship between the clinicopathologic characteristics and the hypomethylation status.

Results: Experimental results showed that 16 (59.26%) BC specimens demonstrated the promoter hypomethylation of HPSE, including 2 cases with complete demethylation. For normal control groups, only 3 specimens (20%) indicated hypomethylation (P<0.05). In addition, the occurrence of hypomethylation increased with the metastasis of positive lymph nodes (P<0.05). Importantly, no significant correlation was found between the hypomethylation of HPSE and the profile of patients including gender, age, tumor size, cancer stage, or histologic grade (P>0.05).

Conclusion: The promoter hypomethylation of HPSE gene is a common epigenetic event occurring in BC and is positively correlated with a poor prognosis. This study suggested that the promoter hypomethylation could be used as a potential biological marker for the early screening of BC.

First Name
Last Name
Email Address
Security code

Abstract View: 22

Your browser does not support the canvas element.

PDF Download: 15

Your browser does not support the canvas element.